AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00316771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 50mg
Description: 50mg po qd
Study NCT00316771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P38 Inhibitor (4) 75mg
Description: 75mg po bid
Study NCT00316771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po bid
Study NCT03563287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail of nine CYP probe drugs
Description: Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules.
Study NCT02122848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiLevel
Description: The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
Study NCT01218503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHOICES - obese
Description: Standard group behavioral weight loss treatment
Study NCT01809379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with doxorubicin and cisplatin
Description: intraperitoneal chemotherapy applied as an aerosol and under pressure
Study NCT01474538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Insulin lispro (100 U/mL) administered by CSII pump
Study NCT01474538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Insulin aspart (100 U/mL) administered by CSII pump
Study NCT03422991 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling and Quality of life questionnaire.
Description: Blood sampling and Quality of life questionnaire.
Study NCT01520324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral delivery mucosal stain
Description: 200mg methylene blue MMX tablet taken prior to colonoscopy
Study NCT01734993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
Study NCT00114972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent
Description: Drug Eluting Stent
Study NCT00114972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Surgery
Description: Coronary Artery Bypass Surgery
Study NCT00916526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial provocation test with mannitol
Description: Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~1. Apply nose clip and subject should be directed to breathe through the mouth~2. Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~3. The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~4. At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~5. At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~6. Insert 5 mg capsule into inhalation device, and proceed as above~7. Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered.
Study NCT03523663 — intervention group
Intervention type: OTHER
Intervention: no intervention. measure eye movement data
Study NCT00773591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NT 201, a Botulinum neurotoxin type A, free of complexing proteins
Description: NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Study NCT02533648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 capsules of allopurinol 150 mg daily for 3 month
Description: 2 capsules of allopurinol 150 mg daily for 3 month
Study NCT02533648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 capsules of lactose daily for 3 month
Description: 2 capsules of lactose daily for 3 month
Study NCT00415350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin Tablet 250 mg daily
Study NCT00415350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 1 daily
Study NCT04559308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: first-line anti-diabetic drug
Study NCT04559308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: First line neoadjuvant chemotherapy protocol
Study NCT04559308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: First line neoadjuvant chemotherapy protocol
Study NCT01979055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Description: 6 session educational intervention (3 telephone, 3 In-person), led by a health educator
Study NCT01979055 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Telephone follow-up
Description: Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
Study NCT00147251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDA approved drugs to treat blood pressure and cholesterol
Study NCT01933958 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
Study NCT03283111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: autologous stem cell transplantation
Study NCT05318014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: dietitian regular nutrition education which was following a low protein diet and supply one serving per day of 6 % low protein formula (200mL,2kcal/ml) for 24 weeks
Study NCT05318014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular nutrition education
Description: dietitian regular nutrition educataion which was following a low protein diet
Study NCT03664661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA nanobody CAR-T cells
Description: step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy.
Study NCT03153956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calibrated AposTherapy®
Description: a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
Study NCT03153956 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Calibrated Sham Apos Therapy Device
Description: The comparator group will receive a non-calibrated sham device.
Study NCT02642029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excitatory TMS
Description: Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
Study NCT02642029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inhibitory TMS
Description: Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
Study NCT02642029 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
Study NCT03886766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
Study NCT03918889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injectable Product
Description: dexmedetomidine infusion at 0.5 µg•kg-1 for 10 min before tracheotomy then adjusted to 0.3µg•kg-1•h-1
Study NCT03918889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: midazolam infusion at 0.05 mg•kg-1 ten minutes before tracheotomy then adjusted to 0.02mg•kg-1•h-1
Study NCT04240470 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Participants will receive endovascular treatment (mechanical thrombectomy) alone without using IV rt-PA.
Study NCT01588639 — intervention group
Intervention type: DRUG
Intervention: Insulin (Scilin N, BAY81-9924)
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
Study NCT01588639 — intervention group
Intervention type: DRUG
Intervention: Insulin (Scilin R _BAY81-9924
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
Study NCT01588639 — intervention group
Intervention type: DRUG
Intervention: Insulin(Scilin M30_BAY81-9924)
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
Study NCT04256096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
Study NCT04256096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
Study NCT04152707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splendor X
Description: The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
Study NCT00773591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT 201, a Botulinum neurotoxin type A, free of complexing proteins
Description: NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Study NCT00992927 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Capsule-Preserving Intra-articular Hydraulic Distension
Description: Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
Study NCT02776176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery Program
Description: optimized peri-operative protocol
Study NCT02776176 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional Program
Description: traditional standard protocol
Study NCT02395627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT02395627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Study NCT00731991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: ART to the levator scapulae.
Study NCT00731991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF
Description: PNF to the levator scapulae.
Study NCT00731991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Treatment
Description: No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
Study NCT03323411 — intervention group
Intervention type: BEHAVIORAL
Intervention: Advance Care Treatment Plan
Description: subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
Study NCT03460899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Euglycaemic Clamp
Description: All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 125/25
Description: 125mcg/ 25mcg QID (Once daily , inhaled)
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719/GW642444 125/25
Description: 125mcg/ 25mcg QID (Once daily , inhaled)
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/GW642444 62.5/25
Description: 62.5mcg/25mcg QID
Study NCT03460899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic/Hypoglycaemic Clamp
Description: All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
Study NCT04134637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
Study NCT04134637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 5 MG/ML
Description: twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
Study NCT04079452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Doravirine 100 mg tablet
Study NCT04079452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Descovy
Description: Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
Study NCT00992927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule-Rupturing Intra-articular Hydraulic Distension
Description: Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
Study NCT03585348 — intervention group
Intervention type: OTHER
Intervention: Neuromuscular blocking agents
Description: Neuromuscular blocking agent ED95 equivalent dose by provider
Study NCT02860455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RAD57 measurement (SpCO)
Description: SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin.
Study NCT02860455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CO-oximeter
Description: COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin.
Study NCT04064385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
Study NCT02395627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT02549053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophagus biopsies (pathologic and healthy zones)
Description: Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
Study NCT02549053 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: esophagus biopsies (healthy zones)
Description: Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
Study NCT03886766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
Study NCT04033198 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Description: patients diagnosed as acute appendicitis , appendectomy done
Study NCT03886766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz solution
Description: Efavirenz solution, 3 mg, oral administration (product 3)
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719/GW642444 62.5/25
Description: 62.5mcg/25mcg QID
Study NCT01086423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib™
Description: Intramuscular, three doses
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 125
Description: 125mcg QID
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 125
Description: 125mcg QID
Study NCT02229968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amicar (ε-aminocaproic acid)
Study NCT01086423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hib™
Description: Intramuscular, three doses
Study NCT01086423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix™
Description: Intramuscular, three doses
Study NCT01517867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chicago Parent Program
Description: The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
Study NCT01517867 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent-Child Interaction Therapy
Description: Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
Study NCT02229968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 62.5
Description: 62.5mcg QID
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 62.5
Description: 62.5mcg QID
Study NCT02517866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil tablets
Study NCT03204461 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
Study NCT03204461 — intervention group
Intervention type: OTHER
Intervention: 1H-magnetic resonance spectroscopy
Description: The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW642444 25
Description: 25mcg QID
Study NCT01323660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW642444 25
Description: 25mcg QID
Study NCT01323660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: placebo
Description: Comparator QID
Study NCT01598025 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation (TBI)
Study NCT01598025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT01598025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT01598025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan